We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Heart Failure Sensor Cuts Hospitalizations in Half

By HospiMedica International staff writers
Posted on 26 Mar 2019
Heart failure (HF) patients show a 58% reduction in hospitalization after implantation of a pulmonary artery (PA) pressure measurement sensor, claims a new study.

The Abbott Vascular (Santa Clara, CA, USA) CardioMEMS Sensor is a permanently implantable wireless device that provides PA pressure measurements, including systolic, diastolic, and mean pressures, which can used to monitor cardiac status and initiate changes in medical therapy if necessary. More...
The sensor consists of a resonant circuit that includes a capacitor and an induction coil; the capacitance is a function of pressure, and the resonant frequency is a function of capacitance. During the RF pulse, the sensor accumulates energy, which is re-radiated to an electronics unit that displays PA information as an 18 second waveform.

A study conducted by the University of Southern California (USC; Los Angeles, USA) showed that patients had an average of 0.52 HF hospitalizations in the year following implantation, compared to 1.24 before, regardless of the patients' ejection fraction. There were also benefits for females (61% reduction), blacks (53% reduction), patients with cardiac implantable electronic devices (CIEDs), and those with an ischemic or non-ischemic cardiomyopathy. The device also appeared to reduce all-cause hospitalizations for arrhythmias, pneumonia, and chronic obstructive pulmonary disease (COPD) by 28%.

CardioMEMS also met its safety endpoint, which was defined as freedom from device or system-related complications or sensor failure at one year post-implantation. Per the study data, only four patients experienced device- or system-related complications, and there was only one episode of sensor failure. The results translate into a 99.7% freedom from device/system-related complications and 99.9% freedom from sensor failure. The study was presented at the American College of Cardiology (ACC) 68th annual scientific session, held during March 2019 in New Orleans (LA, USA).

“If you can maintain more normal cardiac filling pressures and less heart stress, you are less likely to be seriously affected and need hospitalization for other conditions such as lung disease or liver disease, which are affected by heart function,” said lead author and study presenter David Shavelle, MD, of USC. “We believe that having the sensor monitored by their care team also encourages patients to follow their medication plan and gives them a sense of security that is particularly important for those living far away from a hospital.”


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Monitor/Defibrillator
Zenix
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.